CN110747273A - Application of long-chain non-coding RNA LINC00263 in preparation of drug resistance detection preparation for breast cancer - Google Patents

Application of long-chain non-coding RNA LINC00263 in preparation of drug resistance detection preparation for breast cancer Download PDF

Info

Publication number
CN110747273A
CN110747273A CN201911098966.2A CN201911098966A CN110747273A CN 110747273 A CN110747273 A CN 110747273A CN 201911098966 A CN201911098966 A CN 201911098966A CN 110747273 A CN110747273 A CN 110747273A
Authority
CN
China
Prior art keywords
long
linc00263
coding rna
breast cancer
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201911098966.2A
Other languages
Chinese (zh)
Other versions
CN110747273B (en
Inventor
陶永光
刘首娉
刘双
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Central South University
Original Assignee
Central South University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Central South University filed Critical Central South University
Priority to CN201911098966.2A priority Critical patent/CN110747273B/en
Publication of CN110747273A publication Critical patent/CN110747273A/en
Application granted granted Critical
Publication of CN110747273B publication Critical patent/CN110747273B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/6851Quantitative amplification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/166Oligonucleotides used as internal standards, controls or normalisation probes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/178Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention discloses application of long-chain non-coding RNA LINC00263 in preparation of a drug resistance detection preparation for breast cancer. The invention can detect the expression level of the long-chain non-coding RNA LINC00263 in a breast cancer patient, provides a powerful molecular biological basis for predicting resistance to tamoxifen medication and has profound clinical significance and popularization.

Description

Application of long-chain non-coding RNA LINC00263 in preparation of drug resistance detection preparation for breast cancer
Technical Field
The invention belongs to the field of tumor molecular biology, and particularly relates to application of a long-chain non-coding RNA LINC00263 in preparation of a drug resistance detection reagent for breast cancer.
Background
Tamoxifen (tamoxifen) is a non-steroidal antiestrogen widely used in clinical medicine, a Selective Estrogen Receptor Modulator (SERM) of the triphenyldiene series, with estrogen agonist and antagonist properties, and therefore it can act as an estrogen in some tissues while preventing the estrogenic effects in other tissues.
At present, the drug resistance mechanism of the endocrine treatment of breast cancer is complex, other drug treatment schemes are often selected after the endocrine treatment drug resistance condition appears, and the treatment requirement and the psychology of breast cancer patients cannot be met. Therefore, early judgment of endocrine treatment of breast cancer so as to select an optimal treatment scheme and remarkably improve the drug treatment efficiency becomes an important subject to be solved urgently in the field of breast cancer.
Long non-coding RNA (long non-coding RNA) is a general term for non-coding RNA with length more than 200 nt. Initial studies thought it to be "noise" of the transcriptome, but life sciences over the last decade found that they are involved in multiple biological regulatory processes. Researches show that the long-chain non-coding RNA can be used as a very important epigenetic regulation factor in human genome, and can regulate and control DNA methylation, histone modification or chromatin remodeling to silence or activate genes through epigenetic regulation, transcription regulation, post-transcriptional regulation and other mechanisms. In recent years, long-chain non-coding RNA has been paid more attention by researchers as an important regulatory molecule and its application value in clinical diagnosis, chemotherapy sensitivity, prognosis evaluation and the like.
At present, no reference standard and no specific index exist for drug resistance of endocrine treatment of breast cancer, and the requirement for judging the effect of endocrine medication of breast cancer cannot be met. Therefore, determining the endocrine treatment effect to select the optimal treatment scheme and significantly improve the survival rate of patients becomes an important issue to be solved in the field of breast cancer.
Disclosure of Invention
The invention aims to overcome the defects of the prior art, and provides application of long-chain non-coding RNA LINC00263 in preparation of a drug resistance detection preparation for breast cancer.
The long non-coding RNA LINC00263 maps to chromosome 10q 24.31. The inventor finds that the expression of the long-chain non-coding RNA LINC00263 is up-regulated in tamoxifen resistant MCF-7 cells, the expression difference with tamoxifen sensitive MCF-7 cells is obvious (P <0.01) (figure 1), the long-chain non-coding RNA LINC00263 can be used as a judgment standard for judging whether tamoxifen is resistant or not, and can be used as a biomarker for preparing medication guidance of breast cancer patients, namely, the long-chain non-coding RNA LINC00263 is used as a biomarker of a breast cancer tamoxifen medication resistance detection preparation.
Furthermore, the kit (medication guide kit) for detecting the drug resistance of the breast cancer tamoxifen, which has high cost performance and is easy to popularize and apply, can be provided.
The kit comprises a long-chain non-coding RNA LINC00263 real-time fluorescent quantitative PCR specific primer and an ACTB internal reference real-time fluorescent quantitative PCR specific primer; the long-chain non-coding RNA LINC00263 real-time fluorescent quantitative PCR specific primer is as follows:
a forward primer: 5'-TCGGATAGGAGTGTCAGG-3' (SEQ ID NO. 1);
reverse primer: 5'-TTCAGTTGCTTCAGGTCAT-3' (SEQ ID NO. 2);
the ACTB internal reference real-time fluorescent quantitative PCR specific primers are as follows:
a forward primer: 5'-CACCATTGGCAATGAGCGGTTC-3' (SEQ ID NO. 3);
reverse primer: 5'-AGGTCTTTGCGGATGTCCACGT-3' (SEQ ID NO. 4).
The method for detecting the patient with the endocrine therapy of the breast cancer by using the long-chain non-coding RNA LINC00263 comprises the following steps: (1) collecting breast cancer tissues excised after the operation of an individual to be detected, and extracting total RNA; (2) reverse transcribing the long non-coding RNALINC00263 into cDNA by taking the total RNA as a template; (3) carrying out real-time fluorescent quantitative PCR amplification by using a long-chain non-coding RNA LINC00263 specific primer to obtain a relative expression quantity of 2ΔΔCTWhen 2 is presentΔΔCT>5.23, the long-chain non-coding RNA LINC00263 is high in expression.
In conclusion, the invention can be used for detecting the expression level of the long-chain non-coding RNA LINC00263 in a breast cancer patient, provides a powerful molecular biological basis for predicting resistance to tamoxifen medication and has profound clinical significance and popularization.
Drawings
FIG. 1 shows the real-time fluorescent quantitative PCR analysis of the expression difference of the long-chain non-coding RNA LINC00263 in tamoxifen sensitivity and drug resistance.
Detailed Description
EXAMPLE 1 preparation of Long non-coding RNA LINC00263 for tamoxifen guidance kit (50 reactions)
50ml RNA stabilizing solution
2. Isopropanol 100ml
3. Chloroform 100ml
4.Trizol 50ml
5. 10ml of enzyme-free water
6.1 uM random reverse transcription primer 50ul
7.5 Xreverse transcription buffer 200ml
8.10 mM deoxynucleotide triphosphate base 100ul
9.40U/. mu.l RNase inhibitor 500ul
10.200U/. mu.l MMLV reverse transcriptase 50ul
11.Premix Ex Taq 50ul
12.10. mu.M long-chain non-coding RNA LINC00263 real-time fluorescent quantitative PCR specific primer:
the forward primer 5 'TCGGATAGGAGTGTCAGG-3' (SEQ ID NO.1),
reverse primer 5 'TTCAGTTGCTTCAGGTCAT-3' (SEQ ID NO.2),
13.10 μ M internal reference ACTB real-time fluorescent quantitative PCR specific primers:
the forward primer is 5'-CACCATTGGCAATGAGCGGTTC-3' (SEQ ID NO.3),
the reverse primer was 5'-AGGTCTTTGCGGATGTCCACGT-3' (SEQ ID NO. 4).
Example 2 detection of Long non-coding RNA LINC00263 in Breast cancer cells
1. Preservation of breast cancer tissue: collecting breast cancer tissues to be detected, storing the breast cancer tissues in a freezing storage tube filled with RNA stable solution, and placing the breast cancer tissues in a refrigerator at the temperature of minus 80 ℃ for later use.
2. Extraction of RNA from tissues: taking a proper amount of specimen, adding liquid nitrogen into a mortar baked for 6-8h at 180 ℃, grinding the specimen into powder, adding 1ml of Trizol mortar specimen into the mortar, grinding the powder into liquid, transferring the liquid into a centrifuge tube, adding 200 mu l/ml of chloroform into the centrifuge tube, shaking the liquid for 15-30s by hand, standing the liquid on ice for 5min, and centrifuging the liquid for 15min at 12000g at 4 ℃; carefully taking the upper water phase into a new centrifugal tube, adding 0.5ml of precooled isopropanol, uniformly mixing, standing for 20min in a refrigerator at the temperature of-20 ℃, and centrifuging for 10min at the temperature of 4 ℃ at 12000 g; discarding supernatant, adding 1-2ml ethanol diluted with 75% ribozyme-free water, mixing, centrifuging at 4 deg.C for 5min at 7500g, discarding supernatant, drying at room temperature for 5-10min, and adding 10-20 μ l ribozyme-free water to dissolve RNA. The concentration and the quality of RNA are measured by spectrophotometry, the OD260/280 ratio is between 1.8 and 2.0, and the RNA is stored at the temperature of minus 80 ℃.
3. Long non-coding RNA LINC00263 transcription: a reverse transcription kit from Thermo was used. The system for 20. mu.L reverse transcription reaction is shown in Table 1:
TABLE 1
Figure BDA0002269249920000031
Figure BDA0002269249920000041
Reverse transcription first step conditions: 5min at 65 ℃ as shown in Table 2:
TABLE 2
Composition (I) Dosage/tube
5 × reverse transcription buffer 4μl
Base triphosphate deoxynucleotide (10mM) 2μl
RNase inhibitor (40U/. mu.l) 1μl
MMLV reverse transcriptase (200U/. mu.l) 1μl
Products of the first PCR 12μg
Reverse transcription second step procedure: 5 minutes at 25 ℃, 60 minutes at 42 ℃ and 5 minutes at 70 ℃.
4. Carrying out real-time quantitative PCR by using a long-chain non-coding RNA LINC00263 specific primer: the long-chain non-coding RNALINC00263 specific primer sequence is synthesized by Shanghai biological engineering Co.
The transcription product is diluted 5 times and mixed evenly. The 20 μ L reaction system is shown in table 3:
TABLE 3
Composition (I) Dosage/tube
SYBR Premix Ex Taq 10μl
LINC00263 specific primer (10. mu.M) 0.5μl
cDNA products 1μl
Enzyme-free water To 20μl
Real-time fluorescent quantitative PCR reaction program: 95 ℃ for 3 minutes, 40 cycles, 95 ℃ for 10 seconds, 60 ℃ for 30 seconds.
The specific primer sequence of the long-chain non-coding RNA LINC00263 is as follows:
the forward primer 5 'TCGGATAGGAGTGTCAGG-3' (SEQ ID NO.1),
reverse primer 5 'TTCAGTTGCTTCAGGTCAT-3' (SEQ ID NO.2),
5、-2ΔΔCTmeasurement of the index: the experimental data were analyzed by a relatively quantitative analysis method with ACTB as an internal reference gene and using GraphPad Prism software.
Sequence listing
<110> university of south-middle school
Application of long-chain non-coding RNA LINC00263 in preparation of drug resistance detection preparation for breast cancer
<141>2019-10-18
<160>4
<170>SIPOSequenceListing 1.0
<210>1
<211>18
<212>DNA
<213>null(null)
<400>1
tcggatagga gtgtcagg 18
<210>2
<211>19
<212>DNA
<213>null(null)
<400>2
ttcagttgct tcaggtcat 19
<210>3
<211>22
<212>DNA
<213>null(null)
<400>3
caccattggc aatgagcggt tc 22
<210>4
<211>22
<212>DNA
<213>null(null)
<400>4
aggtctttgc ggatgtccac gt 22

Claims (5)

1. The application of the long-chain non-coding RNA LINC00263 in preparing a drug resistance detection preparation for breast cancer is characterized in that the long-chain non-coding RNA LINC00263 is used as a biomarker to prepare the drug resistance detection preparation for breast cancer tamoxifen.
2. The use of claim 1, wherein the use is of the long non-coding RNA LINC00263 as a biomarker for a detection agent.
3. The use of claim 1, wherein the use is the detection of long non-coding RNA RNALINC00263 using a detection kit comprising a long non-coding RNA LINC00263 real-time fluorescent quantitative PCR specific primer and an ACTB internal reference real-time fluorescent quantitative PCR specific primer.
4. The use of claim 3, wherein the long non-coding RNA LINC00263 real-time fluorescent quantitative PCR specific primers are as follows:
a forward primer: 5'-TCGGATAGGAGTGTCAGG-3', respectively;
reverse primer: 5'-TTCAGTTGCTTCAGGTCAT-3', respectively;
the ACTB internal reference real-time fluorescent quantitative PCR specific primers are as follows:
a forward primer: 5'-CACCATTGGCAATGAGCGGTTC-3', respectively;
reverse primer: 5'-AGGTCTTTGCGGATGTCCACGT-3' are provided.
5. A kit for detecting the drug resistance of breast cancer tamoxifen is characterized in that the kit comprises a long-chain non-coding RNAINC 00263 real-time fluorescent quantitative PCR specific primer and an ACTB internal reference real-time fluorescent quantitative PCR specific primer; the long-chain non-coding RNALINC00263 real-time fluorescent quantitative PCR specific primer is as follows:
a forward primer: 5'-TCGGATAGGAGTGTCAGG-3', respectively;
reverse primer: 5'-TTCAGTTGCTTCAGGTCAT-3', respectively;
the ACTB internal reference real-time fluorescent quantitative PCR specific primers are as follows:
a forward primer: 5'-CACCATTGGCAATGAGCGGTTC-3', respectively;
reverse primer: 5'-AGGTCTTTGCGGATGTCCACGT-3' are provided.
CN201911098966.2A 2019-11-12 2019-11-12 Application of long-chain non-coding RNA LINC00263 in preparation of drug resistance detection preparation for breast cancer Active CN110747273B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201911098966.2A CN110747273B (en) 2019-11-12 2019-11-12 Application of long-chain non-coding RNA LINC00263 in preparation of drug resistance detection preparation for breast cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201911098966.2A CN110747273B (en) 2019-11-12 2019-11-12 Application of long-chain non-coding RNA LINC00263 in preparation of drug resistance detection preparation for breast cancer

Publications (2)

Publication Number Publication Date
CN110747273A true CN110747273A (en) 2020-02-04
CN110747273B CN110747273B (en) 2023-04-07

Family

ID=69282992

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201911098966.2A Active CN110747273B (en) 2019-11-12 2019-11-12 Application of long-chain non-coding RNA LINC00263 in preparation of drug resistance detection preparation for breast cancer

Country Status (1)

Country Link
CN (1) CN110747273B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016083458A1 (en) * 2014-11-26 2016-06-02 Ieo - Istituto Europeo Di Oncologia S.R.L. Reprogramming-based models of neurodevelopmental disorders and uses thereof
CN108192974A (en) * 2018-03-02 2018-06-22 中南大学湘雅医院 Applications of the long-chain non-coding RNA LINC00842 as biomarker in adenocarcinoma of lung prognosis detection preparation is prepared
CN108456731A (en) * 2018-03-02 2018-08-28 中南大学湘雅医院 Applications of the long-chain non-coding RNA LINC00336 as biomarker in preparing adenocarcinoma of lung prognosis detection preparation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016083458A1 (en) * 2014-11-26 2016-06-02 Ieo - Istituto Europeo Di Oncologia S.R.L. Reprogramming-based models of neurodevelopmental disorders and uses thereof
CN108192974A (en) * 2018-03-02 2018-06-22 中南大学湘雅医院 Applications of the long-chain non-coding RNA LINC00842 as biomarker in adenocarcinoma of lung prognosis detection preparation is prepared
CN108456731A (en) * 2018-03-02 2018-08-28 中南大学湘雅医院 Applications of the long-chain non-coding RNA LINC00336 as biomarker in preparing adenocarcinoma of lung prognosis detection preparation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
SARAH C.PYFROM等: "PLADDOH:a noval method for functional prediction of long non-coding RNAs identifies cancer-spcific LncRNA activities.", 《BMC GENOMICS》 *
SHOUPIN LIU等: "Annotation and cluster analysis of long noncoding RNA linked to male sex and estrogen in cancers", 《NATURE PARTNER JOURNALS PRECISION ONCOLOGY》 *
许鑫等: "内皮-单核细胞激活多肽-Ⅱ上调LINC00263增强血肿瘤屏障通透性", 《解剖科学进展》 *

Also Published As

Publication number Publication date
CN110747273B (en) 2023-04-07

Similar Documents

Publication Publication Date Title
CN108192976B (en) Application of long-chain non-coding RNA LINC00336 as biomarker in preparation of lung squamous carcinoma prognosis detection preparation
CN108192974B (en) Application of long-chain non-coding RNA LINC00842 as biomarker in preparation of lung adenocarcinoma prognosis detection preparation
CN108456731B (en) Application of long-chain non-coding RNA LINC00336 as biomarker in preparation of lung adenocarcinoma prognosis detection preparation
AU2002246504A1 (en) Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression
WO2002057489A2 (en) Method of determining a chemotherapeutic regimen based on ercc1 and ts expression
CN108179193B (en) Application of METTL14 gene as biomarker in preparation of lung adenocarcinoma prognosis detection preparation
CN111349702A (en) Marker for predicting prognosis of cancer patient and application thereof
Bozorg-Ghalati et al. Molecular biomarkers of anaplastic thyroid carcinoma
CN108624693A (en) Applications of the miR-577 in preparing diagnosis of nephropathy marker
CN110747273B (en) Application of long-chain non-coding RNA LINC00263 in preparation of drug resistance detection preparation for breast cancer
CN108192975B (en) Application of long-chain non-coding RNA LINC00559 as biomarker in preparation of lung squamous carcinoma prognosis detection preparation
CN109182528B (en) Glioblastoma multiforme auxiliary diagnosis and prognosis evaluation kit based on ITGB5 gene and use method thereof
CN103205489B (en) A kind of Micro rna expression detection method and immue quantitative detection reagent box thereof
CN107586844A (en) Glioma prognostic marker Circ9:135881633 | 135883078 application
CN111218512A (en) Breast cancer 21 gene detection kit and application method thereof
CN110734976B (en) Application of long-chain non-coding RNA LINC00263 in preparation of lung adenocarcinoma prognosis detection preparation
CN108192973B (en) Application of long-chain non-coding RNA LINC00559 as biomarker in preparation of lung adenocarcinoma prognosis detection preparation
CN107937528B (en) Glioma prognosis marker hsa _ circ _0125365 and application
CN105255865A (en) Fluorescent quantitative PCR (polymerase chain reaction) detection kit for TYMS (thymidylate synthase) gene expression quantity and application of kit
CN107937539B (en) Glioma prognosis marker hsa _ circ _0135404 and application
CN107937533B (en) Glioma prognostic marker circ7:42148226|42148468 and application thereof
CN107937541B (en) Glioma prognostic marker circ1:1804419|1806538 and application thereof
CN107937535B (en) Glioma prognosis marker circ 7:73686636|73687095 and application thereof
CN107937530B (en) Glioma prognosis marker hsa _ circ _0125361 and application
CN107937542B (en) Glioma prognostic marker circ1:246186743|246186942 and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant